Long-term octreotide treatment prevents
โ
C C Sieber; F Lee; R J Groszmann
๐
Article
๐
1996
๐
John Wiley and Sons
๐
English
โ 210 KB
Chronically portal-hypertensive rats show in vitro vascular hyporeactivity in large part mediated by the endothelium-derived vasodilator nitric oxide. We tested whether long-term octreotide treatment (15 micrograms/kg subcutaneously in 5% D/W, 8-hourly) corrects the in vitro vascular hyporeactivity.